Category: Press Release - Page 72 - Psychedelic Alpha

Read more about the article Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program

Post published:February 16, 2022
Post category:Press Release

Read more about the article Lobe Sciences Ltd. Strengthens Its Balance Sheet

Lobe Sciences Ltd. Strengthens Its Balance Sheet

Post published:February 16, 2022
Post category:Press Release

Read more about the article BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model

Post published:February 15, 2022
Post category:Press Release

Read more about the article Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1

Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1

Post published:February 15, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Post published:February 15, 2022
Post category:Press Release

Read more about the article Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update

Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update

Post published:February 15, 2022
Post category:Press Release

Read more about the article Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

Post published:February 10, 2022
Post category:Press Release

Read more about the article Psyence Group Announces DTC Eligibility Approval in the U.S.

Psyence Group Announces DTC Eligibility Approval in the U.S.

Post published:February 9, 2022
Post category:Press Release

Read more about the article Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders

Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders

Post published:February 9, 2022
Post category:Press Release

Read more about the article MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial

MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial

Post published:February 8, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.